Journal of the National Comprehensive Cancer Network · 2017 · 1K citations · 116 references
MedicineOncologySurgeryMetastasisOncologic SurgerySurgical OncologyCancer StagingMetastatic Cancer ManagementMetastatic Disease ManagementPancreatic CancerPancreatic SurgeryTumor ImagingMetastatic Pancreatic CancerPancreatic Adenocarcinoma SurgeryPancreatic Cancer ImagingPancreatic Cancer ResectionPancreatic Cancer Systemic TherapyPancreatic MetastasesSystemic Therapy IntegrationSystemic Therapy Selection
Ductal adenocarcinoma dominates pancreatic cancers, and high‑quality multiphase imaging distinguishes resectable from unresectable disease while systemic therapy is employed across neoadjuvant, adjuvant, and advanced settings. Clinical trials are essential for advancing pancreatic cancer treatment. The NCCN Guidelines for Pancreatic Adenocarcinoma outline diagnosis and treatment strategies involving systemic therapy, radiation, and surgery.
Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-quality multiphase imaging can help to preoperatively distinguish between patients eligible for resection with curative intent and those with unresectable disease. Systemic therapy is used in the neoadjuvant or adjuvant pancreatic cancer setting, as well as in the management of locally advanced unresectable and metastatic disease. Clinical trials are critical for making progress in treatment of pancreatic cancer. The NCCN Guidelines for Pancreatic Adenocarcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection.
116
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine · 2011 · 7.8K citations · Full text
Medicine, Oncology, Pharmacology +13
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena et al. · New England Journal of Medicine · 2013 · 6.7K citations
Medicine, Oncology, Pharmacology +13
Howard A. Burris, Malcolm J. Moore, John Sahl Andersen et al. · Journal of Clinical Oncology · 1997 · 5.9K citations
Medicine, Oncology, Pharmacotherapy +16
John P. Neoptolemos, Daniel H. Palmer, Paula Ghaneh et al. · The Lancet · 2017 · 1.9K citations · Full text
Medicine, Oncology, Pharmacotherapy +17